Future of Diabetes...What next for Gliptins
Dipeptidyl peptidase-4 (DPP-4) inhibitors, or gliptins, are a relatively new class of oral drugs for type 2 diabetes. These drugs block the DPP-4 enzyme metabolism of incretin hormones, including GLP-1 and GIP. In this issue of Diabetes News Nucleus, let us understand more about gliptins and the future of diabetes management with special focus on this new class of drugs.
Dr. Sanjay Kalra
Dr. Sanjay Kalra, MBBS, MD, DM (AIIMS New Delhi), is an Endocrinologist Based at Bharti Hospital, Karnal, India. An avid researcher, writer, and busy clinician, he is the past president of the Endocrine Society of India (ESI), President of the Indian Professional Association for Transgender Health (IPATH), President of the South Asian Federation of Endocrine Societies (SAFES), and Executive Committee member as well as Chair, Education Working Group at the International Society of Endocrinology (ISE). He is the Section Editor of Endo Text, the PubMed-indexed textbook. He serves as Editor-in-chief Asian Journal of Diabetology while offering his editorial skills to various other publications. Along with these and other responsibilities, he works to spread endocrine and diabetes awareness across the world. In his spare time, he indulges in his favorite hobbies, the folk-dance Bhangra and the traditional Indian club bell, 'Mugdar.'
More FAQs by Dr. Sanjay Kalra
Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks
Please login to comment on this article